Sudan Journal of Medical Sciences
ISSN: 1858-5051
High-impact research on the latest developments in medicine and healthcare across MENA and Africa
Statin-induced Myonecrosis—A Rare Adverse Effect of a Common Drug: A Case Report
Published date: Jun 30 2025
Journal Title: Sudan Journal of Medical Sciences
Issue title: Sudan JMS: Volume 20 (2025), Issue No. 2
Pages: 217 - 223
Authors:
Abstract:
Background: Clinically significant statin-induced myonecrosis is a rare clinical disorder that affects the skeletal muscles of patients taking statin medication. Its clinical presentation ranges from mild muscle pain to muscle weakness associated with significant elevation (>10×) of serum creatinine kinase (CK). Early screening, identification, and treatment of statin-induced myopathy are vital as it may lead to drug discontinuation and poor medication adherence.
Case Report: We report a 40-year-old male diabetic patient who visited our neurology referral clinic with a two-week history of muscle pain associated with proximal extremities’ weakness, which later progressed to involve the distal extremity muscles of his upper and lower limbs. A week before his presentation to our hospital, he became wheelchair-bound. Six months before his admission, he was started on a daily dose of 40 mg oral simvastatin for prevention, given his cardiovascular risk factors. No history of fever, headaches, abnormal body movement; no personal or family history of similar illness; no history of trauma, alcohol use, smoking, or use of herbal medication was elicited. His CK levels were elevated 19 times, and electromyography examination showed a myopathic pattern in proximal muscles. Following the discontinuation of simvastatin, the patient’s muscle weakness significantly improved. In addition, his serum CK levels also lowered significantly on his follow-up evaluation.
Conclusion: This case describes a diabetic patient with statin-induced myonecrosis, managed conservatively through statin withdrawal. It also highlights the benign prognosis in younger patients, showing that the condition generally has a favorable outcome with timely diagnosis and management.
Keywords: statin, myonecrosis, myopathy, diabetes mellitus, creatinine phosphokinase
References:
[1] Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., Bruckert, E., De Backer, G., Krauss, R. M., Laufs, U., Santos, R. D., Hegele, R. A., Hovingh, G. K., Leiter, L. A., Mach, F.,... The European Atherosclerosis Society Consensus Panel (2015). Statin-associated muscle symptoms: Impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 36(17), 1012–1022. https://doi.org/10.1093/ eurheartj/ehv043PMID:25694464
[2] Sathasivam, S. & Lecky, B. (2008). Statin induced myopathy. British Medical Journal, 337, a2296. https://doi.org/10.1136/bmj.a2286
[3] Tomaszewski, M., Stêpie n, K. M, Tomaszewska, J., & Czuczwar, S. J. (2011). Statin-induced myopathies. Pharmacological Reports, 63(4), 859– 866. https://doi.org/10.1016/S1734-1140(11)70601-6
[4] De Cock, E., Hannon, H., Moerman, V., & Schurgers, M. (2018). Statin-induced myopathy: A case report. European Heart Journals—Case Reports, 2(4), 1–4. https://doi.org/10.1093/ehjcr/yty130
[5] Joy, T. R. & Hegele, R. A. (2009). Narrative review: Statin-related myopathy. Annals of Internal Medicine, 150(12), 858–868. https://doi.org/10.7326/ 0003-4819-150-12-200906160-00009
[6] Parker, B. A., Capizzi, J. A., Grimaldi, A. S., Clarkson, P. M., Cole, S. M., Keadle, J., Chipkin, S., Pescatello, L. S., Simpson, K., White, C. M., & Thompson, P. D. (2013). Effect of statins on skeletal muscle function. Circulation, 127(1), 96–103. https://doi.org/10.1161/CIRCULATIONAHA.112.136101
[7] Chew, S. (2009). Statin-induced myopathy in the elderly: Part 1. Adverse Drug Reaction Bulletin, (255), 979–983. https://doi.org/10.1097/FAD. 0b013e32832c0ce1
[8] Kwak, H. (2014). Statin-induced myopathy in skeletal muscle: The role of exercise. Journal of Lifestyle Medicine, 4(2), 71–79. http://dx.doi.org/10.15280/jlm.2014.4.2.71
[9] Sadeeqa, S., Maqsood, M., & Ahmad, M. (2018). Prevalence of statin induced myopathy in Lahore, Pakistan. Pakistan Journal of Pharmaceutical Sciences, 31(2), 617–622.
[10] Neu, A., Hornig, S., Sasani, A., Isbrandt, D., Gerloff, C., Tsikas, D., Schwedhelm, E., & Choe, C. U. (2020). Creatine, guanidinoacetate and homoarginine in statin-induced myopathy. Amino Acids, 52(6– 7), 1067–1069. https://doi.org/10.1007/s00726-020- 02865-w PMID:32594255
[11] Abd, T. T. & Jacobson, T. A. (2011). Statin-induced myopathy: A review and update. Expert Opinion on Drug Safety, 10(3), 373–387. https://doi.org/10.1517/ 14740338.2011.540568
[12] Camerino, G. M., Tarantino, N., Canfora, I., De Bellis, M., Musumeci, O., & Pierno, S. (2021). Statin-induced myopathy: Translational studies from preclinical to clinical evidence. International Journal of Molecular Sciences, 22(4), 2070. https://doi.org/ 10.3390/ijms22042070
[13] Abdulrazaq, M., Hamdan, F., & Al-Tameemi, W. (2015). Electrophysiologic and clinico-pathologic characteristics of statin-induced muscle injury. Iranian Journal of Basic Medical Sciences, 18(8), 737– 744.
[14] Horton, W. B., Taylor, J. S., Ragland, T. J., & Subauste, A. R. (2015). Diabetic muscle infarction: A systematic review. BMJ Open Diabetes Research & Care, 3(1), e000082. https://doi.org/10.1136/bmjdrc-2015- 000082
[15] Apostolopoulou, M., Corsini, A., & Roden, M. (2015). The role of mitochondria in statin-induced myopathy. European Journal of Clinical Investigation, 45(7), 745–754. https://doi.org/10.1111/eci.12461
[16] Sathasivam, S. (2012). Statin induced myotoxicity. European Journal of Internal Medicine,23(4), 317– 324. https://doi.org/10.1016/j.ejim.2012.01.004
[17] Roth, E. M., & Davidson, M. H. (2018). PCSK9 inhibitors: Mechanism of action, efficacy, and safety. Reviews in Cardiovascular Medicine, 19(S1), S31– S46. https://doi.org/10.3909/ricm19S1S0002
